Targeting the “undruggable” RAS with biologics is a research paper published in Advances in cancer research (2022). On theSindex it has a DataRank of 0.477. It has been cited 23 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.477
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: 1I01BX002095
National Institutes of Health
Grant: GM132055
National Institutes of Health
Grant: 7I01BX002095-05
Novel Functions for Ras family GTPases
National Institutes of Health
Grant: 5T32GM132055-05
Cellular, Biochemical and Molecular Sciences Training Program: Developing the skills and expertise needed for a changing biomedical landscape
FWCI
13.82
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 4 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 4 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 5 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 5 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 6 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 6 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 7 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 7 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 2 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 2 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 3 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 1 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 1 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
Additional file 3 of IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers